// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Safety and Tolerability of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients During Sodium Depletion or Irbesartan Coadministration

Stephen Huang - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Angiotensin II

Procollagen Type 1 N-terminal Propeptide, a Collagen Synthesis Biomarker, is Associated With Adverse Clinical Outcome in Patients With Suspected Acute Coronary Syndrome

Thomas Andersen - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Acute Coronary Syndromes

N/A

Evening Dosing of Antihypertensive Treatment is Not Associated With a Better Prognosis

Alejandro De La Sierra - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Non-Invasive Electrocardiographic Mapping of the Human Heart Through a Novel 'Cardiac Magnetic Resonance-Electrocardiographic Imaging' Solution for High Throughput Use

Matthew Webber - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Characterising the Impact of Type Two Diabetes on the Phenotypic Expression of Hypertrophic Cardiomyopathy

Nicholas Jex - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hypertrophic cardiomyopathy

Adenosine

Patients with Post-Acute Sequelae of Sars-cov-2 Syndrome Exhibit No Significant Abnormalities in Cardiac Energetics, Structure, Function, Blood Flow or Tissue Characteristics

Mira Gorecka - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Comprehensive Cardiac Magnetic Resonance Imaging Study for Characterising Remote Myocardial Zone Contractile Function, Perfusion and Fibrosis in Type 2 Diabetes Patients with Prior Myocardial Infarction

Sharmaine Thirunavukarasu - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Myocardial infarction

N/A

Intentional Weight Loss as a Novel Treatment for Heart Failure with Preserved Ejection Fraction

Moritz J Hundertmark - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with preserved ejection fraction

N/A

Applying a Deep-Learning Approach for Automated Quantification of Epicardial Adipose Tissue on Coronary Computed Tomography Angiography in Challenging Clinical Populations

Henry W West - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Angina

N/A

Epicardial Adiposity Measured by a Deep Learning Network, Predicts Mortality and Cardiovascular Events in Patients Undergoing Cardiac CT

Henry W West - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

N/A

Speckle Tracking Echocardiography Changes in Patients Who Developed Atrial Fibrillation Post Coronary Artery Bypass Grafting

Sarath Lal Mannumbeth Renjithlal - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Postoperative atrial fibrillation

N/A

Myocardial Energetic Impairment is the Basis for Reduced Cardiac Reserve and Exercise-Induced Pulmonary Congestion in Heart Failure With Preserved Ejection Fraction: Insights From Novel Cardiopulmonary Magnetic Resonance Imaging

Matthew K Burrage - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Heart failure with preserved ejection fraction

N/A

“BECAUSE THAT’S THEIR JOB, ISN’T IT?”: EXPLORING CHILDREN AND YOUNG PEOPLES’ EXPERIENCES OF AND PERSPECTIVES ABOUT PAIN COMMUNICATION IN PAEDIATRIC RHEUMATOLOGY IN THE UK

R. Lee - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

“MY GUT FEELING IS…”: IDENTIFYING HOW HEALTHCARE PROFESSIONALS COMMUNICATE ABOUT PAIN IN PAEDIATRIC RHEUMATOLOGY MULTI-DISCIPLINARY TEAM MEETINGS

R. Lee - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

2020 GRANT. AWARENESS OF NON-PHARMACOLOGICAL AND NON-SURGICAL TREATMENTS FOR OSTEOARTHRITIS: A SURVEY OF PEOPLE WITH OSTEOARTHRITIS IN SWEDEN.

S. Battista - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

A 24-month Prospective Psoriatic Arthritis Observational Study of Persistence of Treatment (PRO-SPIRIT) - Interim Analysis of Baseline Characteristics

J. Morel - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

ABT-494

A CASE OF SEVERE ANCA ASSOCIATED VASCULITIS AFTER COVID-19 VACCINATION

I. Qaisar - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

A CONCORDANCE STUDY OF CT DENSITOMETRY WITH DXA DENSITOMETRY

R. Mawella - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoporosis

N/A

A MACHINE LEARNING ANALYSIS OF FACTORS PREDICTING ORGAN DAMAGE PROGRESSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS USING THE SPANISH SOCIETY OF RHEUMATOLOGY LUPUS REGISTRY (RELESSER)

J. M. Pego-Reigosa - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

A PATIENT-LED SURVEY INTO THE BENEFITS AND LIMITATIONS OF TELEMEDICINE APPOINTMENTS FOR ASSESSING CHILDREN AND YOUNG PEOPLE WITH RHEUMATIC CONDITIONS: COMPARING EUROPEAN AND CANADIAN COHORTS

R. Beesley - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved